Women with gout: Efficacy and safety of urate-lowering with febuxostat and allopurinol

Arthritis Care and Research

Volumn 64, Issue 2, 2012, Pages 256-261

  Chohan, Saima ^a   Becker, Michael A ^a   MacDonald, Patricia A ^b   Chefo, Solomon ^b   Jackson, Robert L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URATE; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; URIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ARTHROPATHY; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL PAIN; GOUT; HEADACHE; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OSTEOARTHROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HYPERURICEMIA; METABOLIC DISORDER; MIDDLE AGED; OBESITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; ILLINOIS; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SEX FACTORS; THIAZOLES; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 84858054252     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.20680     Document Type: Article

References (18)

1. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6. (Pubitemid 35266034)
2. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7. (Pubitemid 39006641)
3. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58:26-35.
4. National Center for Health Statistics. Health, United States, 2009: with special feature on medical technology. Hyattsville (MD): Centers for Disease Control and Prevention, US Department of Health and Human Services; 2010.
5. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516. (Pubitemid 41379398)
6. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50. (Pubitemid 44168841)
7. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47. (Pubitemid 40215224)
8. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
9. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59: 1540-8.
10. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
11. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34. (Pubitemid 43993484)
12. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993;21:1487-95. (Pubitemid 23312482)
15. Lally EV, Ho G Jr, Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med 1986;146:2221-5. (Pubitemid 17189098)
16. Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, et al. Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991;151:726-32.
17. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006;65:1368-72. (Pubitemid 44641592)
18. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13. (Pubitemid 351571922)